Ataciguat
- Generic Name
- Ataciguat
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19Cl2N3O6S3
- CAS Number
- 254877-67-3
- Unique Ingredient Identifier
- QP166M390Q
- Background
Ataciguat has been investigated for the basic science of Aortic Valve Stenosis.
A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification
- First Posted Date
- 2015-06-25
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 35
- Registration Number
- NCT02481258
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Safety of Ataciguat in Patients With Moderate Calcific Aortic Valve Stenosis
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2016-07-07
- Lead Sponsor
- Jordan D. Miller, Ph.D.
- Target Recruit Count
- 44
- Registration Number
- NCT02049203
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Efficacy and Safety Study of Ataciguat Versus Placebo in Patients With Neuropathic Pain
- First Posted Date
- 2008-12-01
- Last Posted Date
- 2011-04-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 62
- Registration Number
- NCT00799656
- Locations
- 🇷🇴
Sanofi-Aventis Administrative Office, Bucuresti, Romania
Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease
Phase 2
Completed
- Conditions
- Intermittent Claudication
- Interventions
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 553
- Registration Number
- NCT00443287
- Locations
- 🇿🇦
Sanofi-Aventis Administrative Office, Midrand, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath